May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Mycophenolate Mofetil for the Treatment of Severe Inflammatory External Eye Disease Conditions
Author Affiliations & Notes
  • M.R. Wilkins
    Cornea and external disease, Moorfields Eye Hospital, London, United Kingdom
  • J.K. G. Dart
    Cornea and external disease, Moorfields Eye Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships  M.R. Wilkins, None; J.K.G. Dart, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 2664. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M.R. Wilkins, J.K. G. Dart; Mycophenolate Mofetil for the Treatment of Severe Inflammatory External Eye Disease Conditions . Invest. Ophthalmol. Vis. Sci. 2005;46(13):2664.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Abstract:
 

To ascertain the benefits and side effects from using Mycophenolate mofetil (MMF) to treat severe inflammatory external eye disease

 

We performed a retrospective case note review of all patients who had received MMF for severe inflammatory external eye disease at Moorfields Eye Hospital. Patients were identified from an immunosuppression database and from the hospital’s electronic patient record. Patients receiving MMF as prophylaxis for corneal graft rejection were excluded.

 

26 patients were identified, their mean age was 60. All started MMF either because other systemic immunosuppressants had failed to control the inflammation or had not been tolerated. Diagnoses and whether the inflammation was controlled are given in table 1.

 

 

The inflammation was controlled by MMF in 16/26 (61%), partially controlled in 3/26 (12%), and not controlled in 7/26 (27%). Four (4/7) patients whose inflammation was not controlled stopped MMF within 3 months of starting it because they could not tolerate the side effects of the drug. In total 5/26 discontinued MMF because of side effects (diarrhoea, weight gain, nausea and fatigue), 4/26 had some malaise or sweats and were able to continue treatment. Two (2/26) patients stopped MMF because of blood count abnormalities; subsequently these were attributed to other drugs or conditions. Both patients restarted MMF with no adverse effect and achieved good control of their inflammation. One patient discontinued MMF when she became pregnant.

 

Mycophenolate mofetil is quite well tolerated and was successful in controlling inflammation in 61%, and partially successful in a further 12%, of patients with this group of severe inflammatory external eye diseases that had been uncontrolled by other systemic immunosuppressant agents due to drug intolerance or treatment failure.

 

 
Keywords: cornea: clinical science • immunomodulation/immunoregulation • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×